Matthew S. McIlwain - 24 Aug 2021 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role
Director
Signature
/s/ Matt McIlwain
Issuer symbol
NAUT
Transactions as of
24 Aug 2021
Net transactions value
+$285,041
Form type
4
Filing time
26 Aug 2021, 19:29:53 UTC
Previous filing
21 Jun 2021
Next filing
17 Nov 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAUT Common Stock Purchase $104,269 +13,568 +4.2% $7.68 335,673 24 Aug 2021 Direct F1
transaction NAUT Common Stock Purchase $90,458 +11,693 +3.5% $7.74 347,366 25 Aug 2021 Direct F2
transaction NAUT Common Stock Purchase $90,314 +11,709 +3.4% $7.71 359,075 26 Aug 2021 Direct F3
holding NAUT Common Stock 5,798,394 24 Aug 2021 By Madrona Venture Fund VI, LP F4
holding NAUT Common Stock 222,376 24 Aug 2021 By Madrona Venture Fund VI-A, LP F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.56 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.69 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.67 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4 Shares held by Madrona Venture Fund VI, LP ("Madrona Fund VI"). Madrona Investment Partners VI, L.P. ("Madrona Partners VI") is the general partner of Madrona Fund VI, and Madrona VI General Partner, LLC ("Madrona VI LLC") is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5 Shares held by Madrona Venture Fund VI-A, LP ("Madrona Fund VI-A"). Madrona Partners VI is the general partner of Madrona Fund VI-A, and Madrona VI LLC is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of benefical ownership of all of the reported shares for purposes of Section 16 or for any other purpose.